First report of a glycosaminoglycan-xylopyranan from the buccinid gastropod mollusk Babylonia spirata attenuating proinflammatory 5-lipoxygenase.

A previously undescribed xylated glycosaminoglycan characterized as β-D-Xylop(1 → 3)-(⋯ → 4)-GlcpA(1 → 3)-GlcpNAc(1 → ⋯) was purified from the buccinid gastropod Babylonia spirata and was evaluated for pharmacological properties using different in vitro models. The glycosaminoglycan-xylopyranan displayed prospective free radical quenching activities (IC50  < 0.7 mg/ml), whereas it exhibited potentially greater attenuation against the inductive proinflammatory enzyme 5-lipoxygenase (5-LOX, IC50 0.36 mg/ml) than the synthetic nonsteroidal anti-inflammatory drug aspirin (0.42). Gel permeation chromatography analysis specified the average molecular mass of the purified polysaccharide to be 231.88 kDa. The linkage sites, anomeric configuration, and the sequence of sugar residues of the purified xylated glycosaminoglycan were attributed by the inter-residue correlation obtained via two-dimensional nuclear resonance spectroscopic techniques. The results specified that the studied compound was composed of GlcpA(1 → 3)-GlcpNAc (1 → ⋯) disaccharide repeating unit in the glycosaminoglycan backbone, with the xylose residues branching as C-3 substituents of the GlcpA. . PRACTICAL APPLICATIONS: The edible marine buccinid mollusk Babylonia spirata is a gastropod species of economic significance in the coastal regions of peninsular India. A previously unreported xylated glycosaminoglycan with a β-D-Xylop(1 → 3)-(⋯ → 4)-GlcpA(1 → 3)-GlcpNAc(1 → ⋯) framework was isolated to homogenity and was found to possess potential antioxidant and 5-lipoxygenase attenuation activities. The isolated metabolite might be anticipated as potential naturally-derived bioactive constituent in functional food and pharmaceutical applications.